2023
Assessment of Inflammatory Bowel Disease Training Among Gastroenterology Fellows
Al-Bawardy B, Malter L, Ehrlich A, Rieder F, Gaidos J, Proctor D, Windish D. Assessment of Inflammatory Bowel Disease Training Among Gastroenterology Fellows. Inflammatory Bowel Diseases 2023, 29: 1990-1992. PMID: 36810663, PMCID: PMC11491607, DOI: 10.1093/ibd/izad030.Peer-Reviewed Original ResearchOutcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease
Sayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDEndoscopic healingTherapy groupAdvanced therapiesClinical remissionBowel diseaseAcute ascending cholangitisRate of cholangitisSmall bowel involvementThird of patientsAscending cholangitisSclerosing cholangitisAdult patientsBowel involvementSecondary outcomesMedian agePrimary outcomeRetrospective studyHigh riskCholangitisPatientsTherapyLarger study
2021
Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies
Tran AN, Wang M, Hundt M, Chugh R, Ohm J, Grimshaw A, Ciarleglio M, Hung KW, Proctor DD, Price CC, Laine L, Al-Bawardy B. Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies. Journal Of Immunotherapy 2021, 44: 325-334. PMID: 34380976, DOI: 10.1097/cji.0000000000000383.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsDiarrhea/colitisICI therapyCheckpoint inhibitorsObservational studyAnti-programmed cell death-1/Outcomes of ICISystematic reviewCell death-1/Permanent ICI discontinuationReal-world incidenceRemission of diarrheaRecurrence of symptomsDeath-1/Treatment of diarrheaRandom-effects modelICI discontinuationAdvanced malignanciesAppropriate patientsPrimary outcomeOverall incidenceAntigen-4Early treatmentColitisHigh riskConcise Commentary: Ill Preparation for Managing Liver Illness Among Incoming Medical Residents
Proctor DD. Concise Commentary: Ill Preparation for Managing Liver Illness Among Incoming Medical Residents. Digestive Diseases And Sciences 2021, 67: 2086-2086. PMID: 34365538, DOI: 10.1007/s10620-021-07195-9.Peer-Reviewed Original Research
2020
Cutaneous Vasculitis After Ustekinumab Induction in Crohn’s Disease
Chugh R, Proctor DD, Little A, Myung P, Cowper S, Imaeda S, Pashankar DS, Al-Bawardy B. Cutaneous Vasculitis After Ustekinumab Induction in Crohn’s Disease. Inflammatory Bowel Diseases 2020, 27: e30-e31. PMID: 33179735, DOI: 10.1093/ibd/izaa285.Peer-Reviewed Case Reports and Technical NotesThe Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritisThe emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
Damsky W, Peterson D, Ramseier J, Al-Bawardy B, Chun H, Proctor D, Strand V, Flavell RA, King B. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. Journal Of Allergy And Clinical Immunology 2020, 147: 814-826. PMID: 33129886, DOI: 10.1016/j.jaci.2020.10.022.BooksConceptsTranscription pathwayDownstream Janus kinaseJAK-signal transducerSmall molecule inhibitorsSignal transducerJanus kinaseJAK inhibitorsAutoimmune/inflammatory disordersKinase inhibitorsActivatorPathwayInhibitorsCytokine activityInflammatory diseasesImmune systemKinaseOrgan systemsBiologyCytokinesTransducerInhibitionThe Feasibility of Measuring Sleep and Circadian Characteristics in Adults with Inflammatory Bowel Disease
Conley S, Proctor DD, Lehner V, Jeon S, Redeker NS. The Feasibility of Measuring Sleep and Circadian Characteristics in Adults with Inflammatory Bowel Disease. Western Journal Of Nursing Research 2020, 43: 53-59. PMID: 32517546, PMCID: PMC7704942, DOI: 10.1177/0193945920933926.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseBowel diseaseWrist actigraphyInactive inflammatory bowel diseaseActivity diaryElectronic diarySleep/activitySalivary dim light melatonin onsetDim light melatonin onsetRest-activity rhythmWrist actigraphSaliva collectionMelatonin onsetSleepDiseaseActigraphyCircadian characteristicsAdult participantsAdultsCircadian rhythmSalivaDiaryParticipantsRhythmYearsSleep Characteristics and Rest–Activity Rhythms Are Associated with Gastrointestinal Symptoms Among Adults with Inflammatory Bowel Disease
Conley S, Jeon S, Lehner V, Proctor DD, Redeker NS. Sleep Characteristics and Rest–Activity Rhythms Are Associated with Gastrointestinal Symptoms Among Adults with Inflammatory Bowel Disease. Digestive Diseases And Sciences 2020, 66: 181-189. PMID: 32193859, PMCID: PMC8162988, DOI: 10.1007/s10620-020-06213-6.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseRest-activity rhythmHeartburn/refluxDisease activityGI symptomsSleep characteristicsBowel diseaseGas/bloatingCross-sectional studySpecific sleep characteristicsRAR variablesGastrointestinal symptomsIntra-daily variabilityBackgroundSleep disturbancesSleep efficiencyAimsThe purposeSleep onsetSymptomsAdultsDiseaseRefluxPoor qualityAssociationRhythmRemission
2018
Longitudinal Changes in Symptom Cluster Membership in Inflammatory Bowel Disease
Conley S, Jeon S, Proctor DD, Sandler RS, Redeker NS. Longitudinal Changes in Symptom Cluster Membership in Inflammatory Bowel Disease. Journal Of Nursing Scholarship 2018, 50: 473-481. PMID: 29971936, PMCID: PMC6120775, DOI: 10.1111/jnu.12409.Peer-Reviewed Original ResearchConceptsSymptom cluster membershipInflammatory bowel diseaseSymptom burdenBowel diseaseLower symptom burdenPsychological symptoms groupSymptom management optionsHigh symptom burdenRetrospective longitudinal studyLatent transition analysisActive diseaseClinical factorsPain interferenceColitis FoundationSleep disturbancesCluster membershipHigh burdenMultiple symptomsSymptom groupsPhysical symptomsPsychological symptomsLow burdenSymptom clustersLongitudinal changesSymptomsEvolution of Intrahepatic Shunts in a Patient With Hereditary Hemorrhagic Telangiectasia.
Haghighat L, Brandt EJ, Proctor DD, Garcia-Tsao G, Pollak J, Young L. Evolution of Intrahepatic Shunts in a Patient With Hereditary Hemorrhagic Telangiectasia. Annals Of Internal Medicine 2018, 169: 508-509. PMID: 29868721, DOI: 10.7326/l18-0036.Peer-Reviewed Case Reports and Technical Notes
2017
Knowledge Gaps in the Management of Postoperative Crohn’s Disease: A US National Survey
Nguyen VQ, Mays JL, Lang M, Wu Y, Dassopoulos T, Regueiro M, Moss A, Proctor DD, Sorrentino D. Knowledge Gaps in the Management of Postoperative Crohn’s Disease: A US National Survey. Digestive Diseases And Sciences 2017, 63: 53-60. PMID: 29147878, DOI: 10.1007/s10620-017-4844-z.Peer-Reviewed Original ResearchConceptsMedical prophylaxisCrohn's diseaseEndoscopic findingsClinical practicePostoperative Crohn's diseasePrior intestinal surgerySubsequent endoscopic findingsHigh-risk patientsEndoscopic scoring systemEarly disease onsetHigh-risk factorsAmerican Gastroenterological AssociationCurrent clinical practiceCombination of symptomsBackgroundPostoperative recurrenceUS National SurveyEndoscopic recurrenceCD patientsClinical recurrenceIntestinal surgeryMajority of participantsPerianal fistulasResultsA totalDisease onsetPatient riskSymptom clusters in adults with inflammatory bowel disease
Conley S, Proctor DD, Jeon S, Sandler RS, Redeker NS. Symptom clusters in adults with inflammatory bowel disease. Research In Nursing & Health 2017, 40: 424-434. PMID: 28833284, PMCID: PMC5597486, DOI: 10.1002/nur.21813.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseSymptom burdenBowel diseaseHigh symptom burden groupSymptom clustersOutcomes Measurement Information System (PROMIS) measuresLower symptom burdenHigh symptom burdenActive disease stateLatent class analysisSymptom management interventionsSymptom cluster groupsSymptom cluster membershipClinical factorsCrohn's diseasePain interferenceBurden groupRetrospective studyColitis FoundationSleep disturbancesFemale genderReduced qualityPhysical symptomsPsychological symptomsSymptoms
2016
JAK2 Disease-Risk Variants Are Gain of Function and JAK Signaling Threshold Determines Innate Receptor-Induced Proinflammatory Cytokine Secretion in Macrophages
Hedl M, Proctor DD, Abraham C. JAK2 Disease-Risk Variants Are Gain of Function and JAK Signaling Threshold Determines Innate Receptor-Induced Proinflammatory Cytokine Secretion in Macrophages. The Journal Of Immunology 2016, 197: 3695-3704. PMID: 27664279, PMCID: PMC5127452, DOI: 10.4049/jimmunol.1600845.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseAnti-inflammatory cytokinesImmune-mediated diseasesOligomerization domain 2Proinflammatory cytokinesMyeloid cellsJAK2 expressionJAK inhibitorsIntestinal myeloid cellsThymic stromal lymphopoietinUlcerative colitis patientsProinflammatory cytokine secretionPattern recognition receptorsHuman myeloid cellsLower JAK2Cell typesColitis patientsBowel diseaseIL-10IL-22Peripheral macrophagesIL-4Cytokine secretionAA carriersDecreased responseGlobal Health Education in Gastroenterology Fellowship: A National Survey
Jirapinyo P, Hunt RS, Tabak YP, Proctor DD, Makrauer FL. Global Health Education in Gastroenterology Fellowship: A National Survey. Digestive Diseases And Sciences 2016, 61: 3443-3450. PMID: 27796765, DOI: 10.1007/s10620-016-4308-x.Peer-Reviewed Original ResearchConceptsHealth educationIntrahepatic duct stonesElectronic survey studyAmerican Gastroenterological AssociationGastroenterology fellowship programsGlobal health educationFellowship programsHepatitis BHepatitis EDuct stonesInfectious enteritisGastroenterological AssociationResultsThe questionnaireProgram directorsGastroenterology fellowsGastroenterology fellowshipGastroenterology trainingGlobal health curriculaHealth curriculumUnderserved areasMost fellowsGH educationAdequate experienceFellowship curriculumNational surveyA Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn’s Disease and Human Gut Microbiome Composition
Li D, Achkar JP, Haritunians T, Jacobs JP, Hui KY, D'Amato M, Brand S, Radford-Smith G, Halfvarson J, Niess JH, Kugathasan S, Büning C, Schumm LP, Klei L, Ananthakrishnan A, Aumais G, Baidoo L, Dubinsky M, Fiocchi C, Glas J, Milgrom R, Proctor DD, Regueiro M, Simms LA, Stempak JM, Targan SR, Törkvist L, Sharma Y, Devlin B, Borneman J, Hakonarson H, Xavier RJ, Daly M, Brant SR, Rioux JD, Silverberg MS, Cho JH, Braun J, McGovern DP, Duerr RH. A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn’s Disease and Human Gut Microbiome Composition. Gastroenterology 2016, 151: 724-732. PMID: 27492617, PMCID: PMC5037008, DOI: 10.1053/j.gastro.2016.06.051.Peer-Reviewed Original ResearchConceptsCrohn's diseaseMissense variantsMicrobiome compositionGut microbiome compositionInflammatory bowel disease lociCD risk allelesIBD controlsCD patientsUlcerative colitisBlood pressureIBD casesSolute carrier family 39Overweight individualsHealthy controlsLavage samplesLipid levelsFunctional genetic variantsCD casesIndependent cohortHuman gut microbiome compositionReplication cohortGut microbiomeAbstractTextRisk allelesDiseaseAppendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis
Parian A, Limketkai B, Koh J, Brant SR, Bitton A, Cho JH, Duerr RH, McGovern DP, Proctor DD, Regueiro MD, Rioux JD, Schumm P, Taylor KD, Silverberg MS, Steinhart AH, Hernaez R, Lazarev M. Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis. Gut 2016, 66: 1390. PMID: 27196594, PMCID: PMC5065377, DOI: 10.1136/gutjnl-2016-311550.Peer-Reviewed Original ResearchConceptsUC diagnosisDisease courseImpact of appendectomyRisk of colectomyTiming of appendectomyIndependent risk factorMilder disease courseSeverity of diseaseDevelopment of UCColectomy rateFuture colectomyEarly appendectomyClinical courseMultivariable analysisRisk factorsAppendectomyColectomyLarge cohortHigh riskPatientsDiagnosisConsortium databaseNational InstituteRiskUC
2015
Introduction to the “Fellows and Young GIs Section”
To U, Proctor D. Introduction to the “Fellows and Young GIs Section”. Digestive Diseases And Sciences 2015, 61: 354-354. PMID: 26685909, DOI: 10.1007/s10620-015-3995-z.Peer-Reviewed Original Research
2013
EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging
Faubion WA, Fletcher JG, O'Byrne S, Feagan BG, de Villiers WJ, Salzberg B, Plevy S, Proctor DD, Valentine JF, Higgins PD, Harris JM, Diehl L, Wright L, Tew GW, Luca D, Basu K, Keir ME. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging. The American Journal Of Gastroenterology 2013, 108: 1891. PMID: 24126633, DOI: 10.1038/ajg.2013.354.Peer-Reviewed Original ResearchConceptsComputed tomography enterographySerum IL-22Disease activityFecal calprotectinCrohn's diseaseSerum MMP9Ulcerative colitisCross-sectional imagingCD patientsIL-22Serum matrix metalloproteinase-9Bowel wall inflammationInflammatory disease activitySerum interleukin‐22Inflammatory bowel diseaseFindings of inflammationCrohn's disease activityMatrix metalloproteinase-9Endoscopy subscoreTomography enterographyUC patientsEndoscopy scoresBowel diseaseClinical symptomsWall inflammationThe Influence of Depression on Quality of Life in Patients with Inflammatory Bowel Disease
Zhang CK, Hewett J, Hemming J, Grant T, Zhao H, Abraham C, Oikonomou I, Kanakia M, Cho JH, Proctor DD. The Influence of Depression on Quality of Life in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2013, 19: 1732-1739. PMID: 23669400, PMCID: PMC4623582, DOI: 10.1097/mib.0b013e318281f395.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseDisease activity indexHR-QOLCrohn's diseaseUlcerative colitisDisease activityBowel diseaseQuality of lifeActivity indexShort Inflammatory Bowel Disease QuestionnaireDepression InventoryInflammatory bowel disease practiceCrohn's Disease Activity IndexInflammatory Bowel Disease QuestionnairePatients' HR-QOLSeo activity indexBowel Disease QuestionnaireHealth-related qualityPoorer HR-QOLChronic inflammatory disordersPrevalence of depressionBeck Depression Inventory-IIDiagnosis of depressionCross-sectional studyImportance of depression